Solubility properties of racemic praziquantel and its enantiomers

Pharmaceutical Development and Technology

Volumn 3, Issue 4, 1998, Pages 557-564

  El Arini, Silvia Kocova ^a   Giron, Danièle ^b,c   Leuenberger, Hans ^b  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b UNIVERSITY OF BASEL   (Switzerland)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

DSC; Enantiomers; IR spectroscopy; Phase solubility diagrams; Praziquantel; Racemic drug; Solubility; Thermal analysis; X ray diffraction; Cyclodextrin

Indexed keywords

BETA CYCLODEXTRIN; PRAZIQUANTEL;

ARTICLE; DRUG SOLUBILITY; ENANTIOMER; ENTHALPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROMETRY; MELTING POINT; PRIORITY JOURNAL; RACEMIC MIXTURE; THERMAL ANALYSIS; ULTRAVIOLET SPECTROSCOPY; X RAY DIFFRACTION;

EID: 0031739328     PISSN: 10837450     EISSN: None     Source Type: Journal    
DOI: 10.3109/10837459809028638     Document Type: Article

References (17)

1. K. Mislow, Introduction to Stereochemistry, Benjamin, New York, 1966.
2. S.-T. Liu and A. Hurwitz, Effect of enantiomeric purity on solubility determination of dexclamol hydrochloride, J. Pharm. Sci., 67, 636-638 (1978).
3. S. Yalkowsky (ed.), Techniques of Solubilization of Drugs, Marcel Dekker, Inc., New York, 1981, p. 170.
4. A. J. Repta, M .J. Baltezor, and P. C. Bansal, Utilization of an enantiomer as a solution to a pharmaceutical problem: application to solubilization of 1,2-di(4-piperazine-2,6-dione)propane, J. Pharm. Sci., 65, 238-242 (1976).
5. R. D. Doerge, T. C. Daniels, and E. C. Jorgensen, in Textbook of Organic, Medicinal and Pharmaceutical Chemistry, 6th ed. (C. O. Wilson, O. Gisvold, and R. D. Doerge, eds.), Lippincott, Philadelphia, 1971, pp. 31-33.
6. P. Andrews, Praziquantel: mechanisms of anti-schistosomal activity, Pharmacol. Ther., 29, 129-56 (1985).
7. P. Andrews, H. Thomas, R. Pohlke, and J. Seubert, Praziquantel, Med. Res., Rev., 3, 147-200 (1983).
8. Y. H. Lin, M. X. Qian, X. G. Wang, J. Jia, Q. N. Wang, Y. F. Jiang, R. Q. Wang, S. H. Yan, B. Y. Chen, J. S. Li, Z. Y. Qui, and J. K. Shen, Comparative efficacy of praziquantel and its optic isomers in experimental therapy of Schistosoma japonicum in rabbits, Chin. Med. J., 99, 935-940 (1986).
9. S. H. Xiao and B. A. Catto, Comparative in vitro and in vivo activity of racemic praziqunatel and its levorotated isomer on Schistosoma mansoni, J. Inf. Dis., 159, 589-592 (1989).
10. C. S. Bricker, J. W. Depenbusch, J. L. Bennett, and D. P. Thompson, The relationship between tegumental disruption and muscle contraction in Schistosoma mansoni exposed to various compounds, Zeitsch. Parasitenkunde, 69, 61-71 (1983).
11. X. G. Wang, Y. H. Liu, M. X. Qian, S. H. Yan, B. Y. Cheng, Q. N. Wang, X. P. Zheng, J. M. Jin, G. S. Zhang, J. S. Long, T. Wang, T. Huang, and G. J. Xue, Comparative efficacy of levopraziquantel and praziquantel in the treatment of Schistosoma japonicum infection, Acta Chongqing Med. Univ., 12, 9-12 (1987) (in Chinese; English abstract).
12. S. K. El-Arini and H. Leuenberger, Dissolution properties of praziquantel-β-cyclodextrin systems, Pharm. Dev. Technol., 1, 307-315 (1996).
13. T. Higuchi and K. A. Connors, Phase-solubility techniques, Adv. Anal. Chem. Instrum., 4, 117-212, 1965.
14. R. J. Prankerd and S. M. Ahmed, Physicochemical interactions of praziquantel, oxamniquine and tablet excipients, J. Pharm. Pharmacol., 44, 259-261 (1992).
15. United States Pharmacopeia, 23rd ed., National Formulary 18, The United States Pharmacopeial Convention, Rockville, MD, 1995, p. 1274.
16. The Merck Index, 11th ed., Merck and Co. Inc., Rahway, NJ, No. 7714, 1989.
17. A. Burger, K. T. Koller, and W. M. Schiermeier, RS-Ibuprofen and S-Ibuprofen (Dexibuprofen)-Binary system and unusual solubility behavior, Eur. J. Pharm. Biopharm., 43, 142-147 (1996).